Efficacy and safety of tirofiban for percutancous coronary intervention in patients with acute myocardial infarction

Objective:To evaluate the efficacy and safety of tirofiban for percutaneous coronary intervention in patients with acute myocardial infarction. Methods: 60 patients diagnosed AMI were randomly divided into tirofiban group(n=30) who received tirofiban and half-heparin dose, and the control group(n=30),who were treated by full dose heparin during PCI. The coronary TMP flow of IRA after PCI,major adverse cardiac events (MACE) rates within 24 hours and 30 days, bleeding rates were analyzed and compared between the two groups. Results:Three degree TIMI myocardial perfusion of tirofiban group was 96.7%(29/30),but the control group was 80.0%(24/30)(P0.05). The MACE rate of tirofiban group was 6.7%(2/30),but the control group was 16.7%(5/30)(P0.05). There were no difference of complication of bleeding between the two groups.Conclusion:The results suggest that tirofiban is a safe and more efficacious therapy for the patients with AMI during PCI compared with conventional therapy, which can improve the situation of myocardial reperfusion and degree the MACE.